Free Trial
→ Gold Hits New Highs as Global Markets Spiral (From Premier Gold Co) (Ad)
NASDAQ:XCUR

Exicure 8/13/2024 Earnings Report

Exicure logo
$10.50 -0.23 (-2.14%)
Closing price 05/6/2025 03:59 PM Eastern
Extended Trading
$10.77 +0.27 (+2.61%)
As of 07:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Earnings History

Exicure EPS Results

Actual EPS
-$0.07
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Exicure Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Exicure Announcement Details

Quarter
Date
8/13/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Exicure's next earnings date is estimated for Wednesday, June 4, 2025, based on past reporting schedules.

Conference Call Resources

Exicure Earnings Headlines

Short Interest in Exicure, Inc. (NASDAQ:XCUR) Declines By 19.8%
May 4 at 2:25 AM | americanbankingnews.com
Why Exicure Inc. (XCUR) Soared on Monday
April 22, 2025 | msn.com
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
May 7, 2025 | Premier Gold Co (Ad)
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma
April 14, 2025 | businesswire.com
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in ...
April 11, 2025 | gurufocus.com
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)
April 11, 2025 | investing.com
See More Exicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Exicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Exicure and other key companies, straight to your email.

About Exicure

Exicure (NASDAQ:XCUR), an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

View Exicure Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles